Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087536 | 1.00 | TERT (0.38) | TERTOPRM1OPRD1OPRK1MME | |
| SCHEMBL4086999 | 0.92 | TERT (0.38) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4082330 | 0.90 | DPP4 (0.35) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2860996 | 0.89 | TERT (0.45) | TERTMMEACECPA1ACE2 | |
| SCHEMBL2860992 | 0.89 | TERT (0.45) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4086885 | 0.88 | ENPEP (0.31) | TERT | |
| SCHEMBL4099835 | 0.87 | TERT (0.40) | TERTMMEACECPA1ACE2 | |
| SCHEMBL4092645 | 0.87 | TERT (0.35) | TERT | |
| SCHEMBL4096852 | 0.86 | TERT (0.39) | TERTOPRM1OPRD1MMEACE | |
| SCHEMBL4082464 | 0.82 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | TERT 3633/4885OPRM1 1981/4885OPRD1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.